MktsMarkets

Recursion Pharmaceuticals, Inc.
NASDAQ: RXRXKey statistics
RXRX News
Stories mentioning RXRX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6,472 | 35,538 | 5,175 | 19,223 | 14,745 | 4,546 | 26,082 | 14,417 |
| Cost of Goods Sold | 12,490 | 14,276 | 14,687 | 20,161 | 21,829 | 12,794 | 12,079 | 9,199 |
| Gross Profit | (6,018) | 21,262 | (9,512) | (938.00) | (7,084) | (8,248) | 14,003 | 5,218 |
| Operating Expenses | ||||||||
| Research & Development | 87,896 | 95,939 | 121,062 | 128,636 | 129,634 | 98,333 | 74,600 | 73,928 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (128,505) | (108,335) | (172,202) | (176,227) | (191,368) | (183,767) | (98,354) | (100,543) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (122,108) | (108,103) | (162,250) | (171,897) | (202,645) | (178,898) | (95,675) | (98,063) |
| Tax Provision | (4,604) | 19.00 | 3.00 | 0.00 | (158.00) | 8.00 | 167.00 | (523.00) |
| Net Income (Loss) | (117,504) | (108,122) | (162,253) | (171,897) | (202,487) | (178,906) | (95,842) | (97,540) |
| Earnings Per Share (Basic) | (0.22) | (0.24) | (0.36) | (0.41) | (0.50) | (0.65) | (0.34) | (0.40) |
| Earnings Per Share (Diluted) | (0.22) | (0.24) | (0.36) | (0.41) | (0.50) | (0.65) | (0.34) | (0.40) |
| Weighted Average Shares Outstanding (Basic) | 529,304 | 447,446 | 446,988 | 417,361 | 402,772 | 274,207 | 282,583 | 242,196 |
| Weighted Average Shares Outstanding (Diluted) | 529,304 | 447,446 | 446,988 | 417,361 | 402,772 | 274,207 | 282,583 | 242,196 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RXRX
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a stock listed on the Nasdaq Stock Market under the ticker symbol RXRX. It last traded at $4.03 (Oct 30, 2026, 4:00 PM ET), down 5.0% on the day. That gives Recursion Pharmaceuticals a market capitalisation of $2.4B.
Over the past 52 weeks RXRX has traded between $2.77 and $5.84.
Revenue for the quarter ended Mar 31, 2026 was $6.5M; a net loss of $117.5M. Revenue was down 56.1% from $14.7M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $6.5M | -$117.5M | -1815.6% |
| Dec 31, 2025 | $35.5M | -$108.1M | -304.2% |
| Sep 30, 2025 | $5.2M | -$162.3M | -3135.3% |
| Jun 30, 2025 | $19.2M | -$171.9M | -894.2% |
From Recursion Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…